As Bristol Myers Squibb braces for increasing generic competition this decade, the company is counting on its newer medicines to drive growth. Now, one of those new launches has picked up a key early endorsement in England.
In draft guidance (PDF), England's National Institute for Health and Care Excellence (NICE) has signed off on BMS' Camzyos to be used as an add-on to standard care for patients with obstructive hypertrophic cardiomyopathy. The decision means that once approved, the drug will be available to about 7,000 people with the disease on England's National Health Service, NICE said.
The drug has yet to be approved by England's Medicines and Healthcare Products Regulatory Agency (MHRA), so the guidance won't become final until Camyzos' approval in the country.
Further, the drug's list price remains "commercial in confidence" until the MHRA approval comes down, NICE said in its draft guidance. BMS has agreed to a "confidential commercial arrangement" and will provide the drug to NHS at a discount.
Bristol's Camzyos is one of several key launches the company is counting on to drive growth through the next decade. Last year, the company's big-selling multiple myeloma drug Revlimid started facing limited generic competition in the U.S., and that pressure will only grow as time goes on. Bristol execs have said Camzyos could reach $4 billion in sales by 2029.
Looking forward, BMS' PD-1 inhibitor Opdivo and the Pfizer-shared blood thinner Eliquis will also begin to face generics later this decade. With Opdivo, Eliquis and Revlimid representing about 65% of Bristol's overall 2022 sales, executives know it's time to seriously consider how the company can fill the gap from looming generics.
Aside from Camzyos, Bristol is counting on melanoma drug Opdualag and plaque psoriasis treatment Sotyktu to help grow sales in the years to come. In all, BMS hopes that seven drugs launched since 2020 will bring more than $25 billion in combined sales by 2030.
In addition, the company is continually scouting for medicines to add to its portfolio through M&A, executives said in April. Camzyos itself came from the company's $13.1 billion acquisition of MyoKardia in 2020.
We need your help to tell the industry's stories from the COVID pandemic. Please submit a clear photo and a short description to [email protected]. Click here to learn more.